2021
Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors
Liu Y, Liu G, Wang J, Zheng ZY, Jia L, Rui W, Huang D, Zhou ZX, Zhou L, Wu X, Lin S, Zhao X, Lin X. Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors. Science Translational Medicine 2021, 13 PMID: 33762437, DOI: 10.1126/scitranslmed.abb5191.Peer-Reviewed Original ResearchConceptsCAR T cellsT cell receptorSolid tumorsChimeric antigen receptor T-cell therapyMultiple solid tumor modelsRefractory solid tumorsT-cell therapyDurable disease controlHigh response rateSynthetic T cell receptorsB-cell malignanciesHigh antigen sensitivitySolid tumor modelsAntigen recognition domainClinical benefitAntigen stimulationTumor relapseLimited efficacyAntigen sensitivityAntitumor effectsCell malignanciesResponse rateNotable toxicityTumor modelDisease control
2020
CX-2009, a CD166-directed probody drug conjugate (PDC): Results from the first-in-human study in patients (Pts) with advanced cancer including breast cancer (BC).
Boni V, Burris III H, Liu J, Spira A, Arkenau H, Fidler M, Rosen L, Sweis R, Uboha N, Sanborn R, O'Neil B, Harding J, LoRusso P, Weise A, Garcia-Corbacho J, Victoria I, Frye J, Li R, Stroh M, Meric-Bernstam F. CX-2009, a CD166-directed probody drug conjugate (PDC): Results from the first-in-human study in patients (Pts) with advanced cancer including breast cancer (BC). Journal Of Clinical Oncology 2020, 38: 526-526. DOI: 10.1200/jco.2020.38.15_suppl.526.Peer-Reviewed Original ResearchTreatment-related adverse eventsBreast cancerQ3w scheduleAdvanced cancerGrade 3 treatment-related adverse eventsHuman studiesCommon treatment-related adverse eventsMultiple solid tumor modelsInfusion-related reactionsPhase II doseAdvanced solid tumorsDose-escalation phaseDose-escalation studyPhase II expansionClinical trial informationPopulation pharmacokinetic simulationsMicrotubule inhibitorsSolid tumor modelsTumor-associated proteasesCX-072Prior therapyQ2W dosingQ3W dosingAdverse eventsPartial response
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply